Our Pricing

Wegovy Starter Dose UK: How to Access Discount Pricing

Published on: June 03, 2026

Searching for a wegovy starter dose uk discount code? At Cured Pharmacy, you'll access genuine UK-licensed Wegovy from £79.00 with transparent upfront pricing, no hidden fees, and a free clinical consultation completed in under three minutes. Our UK-registered prescribers assess every patient individually to ensure Wegovy is clinically appropriate for your weight loss journey.

Understanding Wegovy Starter Doses and UK Pricing

Wegovy (semaglutide) is a once-weekly injectable GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. The starter dose protocol begins at 0.25 mg weekly for the first month, gradually increasing over 16 weeks to the maintenance dose of 2.4 mg to minimise gastrointestinal side effects whilst optimising tolerability.

At Cured Pharmacy, Wegovy starter doses begin at £79.00, significantly lower than typical UK market rates. This pricing includes your medication, free clinical assessment by a UK prescriber, and discreet home delivery. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets stringent UK pharmaceutical standards before dispensing.

The dose escalation schedule is clinically important. In the STEP 1 trial, participants following the gradual titration protocol experienced an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. Rushing this escalation increases the likelihood of nausea, vomiting, and treatment discontinuation, which is why UK prescribers follow the licensed dosing schedule precisely.

How Wegovy Works: The Science Behind Semaglutide

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a naturally occurring hormone that regulates appetite and glucose metabolism. When you inject Wegovy subcutaneously once weekly, it binds to GLP-1 receptors in the brain's appetite centres, specifically the hypothalamus, reducing hunger signals and increasing satiety after meals [2].

Unlike older weight loss medications that work peripherally, semaglutide crosses the blood-brain barrier to directly influence neural pathways controlling food intake. This central mechanism explains why clinical trial participants report feeling genuinely less hungry rather than simply experiencing appetite suppression through gastrointestinal discomfort.

Wegovy also slows gastric emptying, meaning food remains in your stomach longer, prolonging the feeling of fullness. Additionally, it improves insulin sensitivity and reduces glucagon secretion, which helps stabilise blood glucose levels throughout the day [2]. These combined effects create a metabolic environment conducive to sustained weight loss when paired with lifestyle modifications.

Clinical Trial Evidence for Wegovy

The STEP clinical trial programme enrolled over 4,500 adults across five major studies. STEP 1, the largest trial, demonstrated that 83.5% of participants on Wegovy 2.4 mg achieved at least 5% body weight reduction, compared to 31.1% on placebo [1]. More impressively, 66.1% achieved at least 10% weight reduction, and 48.0% lost 15% or more of their initial body weight.

STEP 2 specifically examined patients with type 2 diabetes, showing an average 9.6% weight reduction over 68 weeks alongside improved glycaemic control [3]. These results positioned semaglutide as a dual-benefit treatment for patients managing both obesity and diabetes, though Wegovy is licensed specifically for weight management rather than diabetes treatment in the UK.

Wegovy Starter Dose UK Discount Code: How It Works at Cured Pharmacy

Our pricing structure is straightforward: Wegovy starts at £79.00 for your initial prescription, with no consultation fees, no hidden charges, and no requirement to enter promotional codes at checkout. This represents a £79.00 saving compared to our standard pricing, automatically applied to weight loss treatments.

After completing your free online consultation, a UK-registered prescriber reviews your medical history, current medications, and weight loss goals. If Wegovy is clinically appropriate, your prescription is issued electronically to our GPhC-registered pharmacy (9012511), and your medication is dispensed the same day for next-day delivery in discreet, unmarked packaging.

Subsequent prescriptions follow the dose escalation schedule your prescriber determines. Most patients progress through 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg over approximately four months. Pricing adjusts according to dose strength, with transparent costs displayed before each prescription approval.

Why Transparent Pricing Matters

Many UK online pharmacies hide final costs until after consultation, creating frustration when patients discover prices exceed their budget. At Cured Pharmacy, you see exact pricing before starting your assessment, allowing informed decisions about your treatment. This transparency reflects our commitment to ethical pharmaceutical practice and patient autonomy.

Wegovy vs Other Weight Loss Injections: Clinical Comparison

The UK weight loss injection market includes several GLP-1 receptor agonists, each with distinct pharmacological profiles. Wegovy contains semaglutide, whilst Saxenda contains liraglutide, an earlier-generation GLP-1 analogue requiring daily injections. Clinical head-to-head trials show semaglutide produces greater weight reduction than liraglutide, with the added convenience of weekly rather than daily administration [4].

Mounjaro (tirzepatide) represents a newer dual GIP/GLP-1 receptor agonist, activating two incretin pathways simultaneously. In the SURMOUNT-1 trial, tirzepatide demonstrated average weight reductions of 15.0% to 20.9% depending on dose, numerically higher than semaglutide's results, though no direct comparative trial exists [5]. However, tirzepatide is currently licensed in the UK for type 2 diabetes management, with weight management licensing anticipated.

Your choice between these medications depends on clinical factors including BMI, comorbidities, previous treatment responses, and tolerance to gastrointestinal side effects. UK prescribers consider these variables during consultation to recommend the most appropriate option for your individual circumstances.

Common Side Effects and How to Manage Them

Gastrointestinal side effects are the most frequently reported adverse events with Wegovy, affecting up to 44% of trial participants [1]. Nausea, typically mild to moderate, peaks during dose escalation phases and usually subsides within several weeks as your body adapts to the medication. Eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce nausea severity.

Diarrhoea and constipation affect approximately 30% and 24% of patients respectively. Maintaining adequate hydration (at least 2 litres daily) and increasing dietary fibre helps regulate bowel movements. If constipation persists beyond two weeks, speak with your prescriber about appropriate laxative options compatible with semaglutide.

Rare but serious side effects include pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies but not confirmed in humans). If you experience severe abdominal pain radiating to your back, persistent vomiting, or a lump in your neck, seek immediate medical attention. Your prescriber will screen for contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 before prescribing Wegovy [2].

When to Contact Your Prescriber

Contact your UK prescriber if side effects interfere with daily activities, persist beyond four weeks, or worsen despite dietary modifications. Your dose escalation schedule may need adjustment, or an alternative weight loss treatment may be more suitable. Never adjust your Wegovy dose independently without prescriber guidance, as this increases the risk of adverse effects and reduces treatment efficacy.

Who Can Use Wegovy: Eligibility Criteria in the UK

NICE guidelines and MHRA licensing specify that Wegovy is indicated for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [6]. Patients must also commit to a reduced-calorie diet and increased physical activity, as Wegovy is licensed as an adjunct to lifestyle intervention, not a standalone treatment.

Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe renal impairment, or diabetic retinopathy. Pregnant or breastfeeding women cannot use Wegovy due to insufficient safety data. Women of childbearing potential should use effective contraception and discontinue Wegovy at least two months before planned conception [2].

During your online consultation at Cured Pharmacy, our UK prescribers assess these criteria alongside your current medications to identify potential drug interactions. Semaglutide can delay gastric emptying, affecting absorption of oral medications, particularly those requiring rapid onset like pain relief or antibiotics. Your prescriber will advise on timing adjustments if necessary.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 392(10148), 637–649. https://doi.org/10.1016/S0140-6736(18)31773-2 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to lifestyle modifications including reduced-calorie diet and increased physical activity.